Basel, Switzerland (ots/PRNewswire) - Results of the landmark VICTOR study presented today at the American Transplant Congress, San Francisco, USA, have shown that Valcyte (oral valganciclovir) is as effective and as well tolerated as intravenous ganciclovir, the current gold-standard for the treatment of cytomegalovirus (CMV) infection in solid organ transplant patients(1),(2). This is good news ...
From: www.campus-med.de
valganciclovir) as Effective as iv Ganciclovir for Treatment of CMV Disease in ...
Posted by Ruslan Abuzant at 10:37 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment